Who are Werewolf Therapeutics, Inc.'s main suppliers?

Werewolf Therapeutics, Inc. (HOWL) key suppliers include: Jazz Pharmaceuticals plc, Jazz Pharmaceuticals plc, Ascendis Pharma A/S, Ascendis Pharma A/S, Bristol-Myers Squibb Company and 13 more. View the full supplier network at chainsifter.com/chain/HOWL.

Who are Werewolf Therapeutics, Inc.'s major customers?

Werewolf Therapeutics, Inc. (HOWL) key customers include: Jazz Pharmaceuticals plc, Jazz Pharmaceuticals plc, CELG-RI, CELG-RI. View the full customer network at chainsifter.com/chain/HOWL.

What sector is Werewolf Therapeutics, Inc. in?

Werewolf Therapeutics, Inc. (HOWL) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

HOWL Supply Chain: Werewolf Therapeutics, Inc. Supplier List & 24 Relationships

18Suppliers

4Customers

2Debt Items

20Related Chains

Werewolf Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
JAZZ	Jazz Pharmaceuticals plc	90%	Reciprocal relationship from JAZZ graph: Reciprocal relationship from HOWL graph: Jazz generally reimbursed us for the cost of such activities.
JAZZ	Jazz Pharmaceuticals plc	90%	Jazz generally reimbursed us for the cost of such activities.
ASND	Ascendis Pharma A/S	72%	lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme…
ASND	Ascendis Pharma A/S	72%	Reciprocal relationship from ASND graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from ASND graph: Reciprocal relationship from HOWL graph: lines and the superior response obt…
BMY	Bristol-Myers Squibb Company	72%	lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme…
BMY	Bristol-Myers Squibb Company	72%	Reciprocal relationship from BMY graph: Reciprocal relationship from HOWL graph: lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cy…
BMYMP	Bristol-Myers Squibb Co	72%	lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme…
BMYMP	Bristol-Myers Squibb Co	72%	Reciprocal relationship from BMYMP graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from HOWL graph: lines and the superior response o…
CELG-RI	CELG-RI	72%	ization will cease to be renewed. We and our contract manufacturers are subject to significant regulation. The manufacturing facilities on which we rely may not continue to meet regulatory requiremen…
CELG-RI	CELG-RI	72%	Reciprocal relationship from CELG-RI graph: Reciprocal relationship from HOWL graph: ization will cease to be renewed. We and our contract manufacturers are subject to significant regulation. The man…
CUE	Cue Biopharma, Inc.	72%	Reciprocal relationship from CUE graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from CUE graph: Reciprocal relationship from HOWL graph: lines and the superior response obtai…
CUE	Cue Biopharma, Inc.	72%	lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from MRK graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from MRK grap…
MRK	Merck & Co., Inc.	72%	lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme…
TKPHF	Takeda Pharmaceutical Company Limited	72%	Reciprocal relationship from TKPHF graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from HOWL graph: lines and the superior response o…
TKPHF	Takeda Pharmaceutical Company Limited	72%	lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme…
XLO	Xilio Therapeutics, Inc.	72%	Reciprocal relationship from XLO graph: Reciprocal relationship from HOWL graph: lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cy…
XLO	Xilio Therapeutics, Inc.	72%	lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme…

Werewolf Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
JAZZ	Jazz Pharmaceuticals plc	90%	Jazz acquired exclusive global development and commercialization rights to WTX-613, which has subsequently been designated JZP898, as well as products containing certain isolated recombinant polypept…
JAZZ	Jazz Pharmaceuticals plc	90%	Reciprocal relationship from JAZZ graph: Reciprocal relationship from HOWL graph: Jazz acquired exclusive global development and commercialization rights to WTX-613, which has subsequently been desig…
CELG-RI	CELG-RI	72%	, the court held that actions to challenge a federal regulation under the APA can be initiated within six years of the date of injury to the plaintiff, rather than the date the rule is finalized. The…
CELG-RI	CELG-RI	72%	Reciprocal relationship from CELG-RI graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from HOWL graph: , the court held that actions…

Werewolf Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
HOWL-DEBT	Debt stack $8.8M	90%	Market cache reports total debt of $8.8M.
HOWL-DEBT-10057	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.

Werewolf Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Werewolf Therapeutics, Inc..

Werewolf Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
HOWL-OWNER-RA-CAPITAL-MANAGEMENT-L-P	RA CAPITAL MANAGEMENT, L.P.	90%	13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 49 tracked holders.

Werewolf Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CELG-RI	BRISTOL MYERS SQUIBB CO	100.00	1	['customer', 'supplier']
DYN	Dyne Therapeutics, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
EMMA	Emmaus Life Sciences, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
BEAM	Beam Therapeutics Inc.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2

Werewolf Therapeutics, Inc. Supply Chain